Patients with certain GLP1R variants may experience stronger appetite suppression and nausea initially, while others tolerate increases more smoothly
There is also a need to design additional experiments in the context of diabetes aimed at comparing the cardiovascular effects of incretin-based therapies to other glucose-lowering therapies and analyzing in depth the impact such therapies may have on different comorbid conditions associated with this disease, including obesity, hyperlipidemia, high blood pressure, renal failure, and so on.72 In this same conceptual framework, experiments to compare the cardioprotective efficacy of different therapies based on GLP-1 should be considered, particularly because GLP-1R and DPP-4 inhibitors have different actions depending on whether they are assessed in the metabolic or cardiovascular setting.14,72,73 In this regard, mention should be made of the multiple experimental observations attributing a cardioprotective activity to the GLP-1 (936) peptide, whose blood levels may be influenced by the type of incretin-based therapy administered
Rotate sites weekly
383 Role of glucagon in the development of type 2 diabetes in 548 participants with prediabetes: a post-hoc analysis of two randomised controlled trials M
C max and T max were reported as observed values
Find even more answers at our FAQ hub
